The stock of 2seventy bio Inc (TSVT) has gone down by -8.47% for the week, with a -7.89% drop in the past month and a 20.00% rise in the past quarter. The volatility ratio for the week is 6.66%, and the volatility levels for the past 30 days are 6.50% for TSVT. The simple moving average for the past 20 days is -6.95% for TSVT’s stock, with a -3.91% simple moving average for the past 200 days.
Is It Worth Investing in 2seventy bio Inc (NASDAQ: TSVT) Right Now?
Company’s 36-month beta value is 1.78.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TSVT is 48.21M, and currently, short sellers hold a 10.65% ratio of that floaft. The average trading volume of TSVT on September 25, 2024 was 400.72K shares.
TSVT) stock’s latest price update
The stock price of 2seventy bio Inc (NASDAQ: TSVT) has plunged by -9.43 when compared to previous closing price of 4.77, but the company has seen a -8.47% decline in its stock price over the last five trading sessions. reuters.com reported 2024-09-25 that 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.
Analysts’ Opinion of TSVT
Many brokerage firms have already submitted their reports for TSVT stocks, with Goldman repeating the rating for TSVT by listing it as a “Sell.” The predicted price for TSVT in the upcoming period, according to Goldman is $2 based on the research report published on June 06, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see TSVT reach a price target of $18, previously predicting the price at $5. The rating they have provided for TSVT stocks is “Outperform” according to the report published on January 31st, 2024.
TSVT Trading at -5.61% from the 50-Day Moving Average
After a stumble in the market that brought TSVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.50% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 6.66%, as shares sank -5.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.81% lower at present.
During the last 5 trading sessions, TSVT fell by -8.26%, which changed the moving average for the period of 200-days by +63.40% in comparison to the 20-day moving average, which settled at $4.63. In addition, 2seventy bio Inc saw 1.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSVT starting from Snow Jessica, who sale 7,816 shares at the price of $4.32 back on Aug 14 ’24. After this action, Snow Jessica now owns 156,330 shares of 2seventy bio Inc, valued at $33,760 using the latest closing price.
JESSICA SNOW, the Officer of 2seventy bio Inc, proposed sale 7,816 shares at $4.32 during a trade that took place back on Aug 14 ’24, which means that JESSICA SNOW is holding shares at $33,760 based on the most recent closing price.
Stock Fundamentals for TSVT
Current profitability levels for the company are sitting at:
- -4.69 for the present operating margin
- 0.48 for the gross margin
The net margin for 2seventy bio Inc stands at -3.54. The total capital return value is set at -0.44. Equity return is now at value -51.89, with -25.54 for asset returns.
Based on 2seventy bio Inc (TSVT), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.6. The debt to equity ratio resting at 1.07. The interest coverage ratio of the stock is -44.78.
Currently, EBITDA for the company is -206.42 million with net debt to EBITDA at -0.9. When we switch over and look at the enterprise to sales, we see a ratio of 8.2. The receivables turnover for the company is 2.43for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.76.
Conclusion
In a nutshell, 2seventy bio Inc (TSVT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
